MedImpact Healthcare Systems, Inc.’s Post

Although only 1% of #pharmacy claims for commercial plans are for #specialtydrugs, these therapies often account for more than 50% of all prescription benefits spending. Let’s find a time to chat about how integrating clinical services and advanced data #analytics can help reduce specialty spend. https://okt.to/ES7Ljn #wearemedimpact #atruepartner #healthcare #pharmacybenefits

Although only 1% of #pharmacy claims for commercial plans are for #specialtydrugs, these therapies often account for more than 50% of all prescription benefits spending. Let’s find a time to chat about how integrating clinical services and advanced data #analytics can help reduce specialty spend. https://okt.to/4GjS5w #wearemedimpact #atruepartner #healthcare #pharmacybenefits

It takes time and a lot of money for companies to develop a medication, prove it's safe and efficacious, and then bring it to the public. The cost of this lengthy process is seen in our drug pricing. However, to ensure that those needing the medications most can afford treatment, changes must be made! Read more about the process at https://lnkd.in/dqUFZ4yH #healthcare #healthtech #innovation #biopharma #ETF #investing #medicine #drugdevelopment

Get the latest in-depth news and analysis on #pharma and #healthcare - subscribe to pharmaphorum today! https://lnkd.in/eGzMs9fB

While biosimilars are are seen as the key to reducing pharmacy costs and expanding drug access, some barriers exist that might be stifling that growth. Many doctors, just like with generics, don't always know they exist yet to prescribe them. Similarly, patients are wary of biosimilars and might not be as receptive to getting prescribed something they are unfamiliar with. Patients who are looking to switch from their current medication to a biosimilar should talk to their doctor about how to successfully navigate the process, but overall the skepticism is unfounded. #healthcare #healthinsurance

Economists can't agree on the U.S. recession's direction, but payers must stay prepared. Check out our latest blog for 5 recession-proof strategies to balance operational efficiencies and high-quality care: 1️⃣ Payer/Provider Collaboration 2️⃣ Utilization Management 3️⃣ Drug Formulary Optimization 4️⃣ Biosimilar Drugs 5️⃣ Electronic Document Exchange Learn more: https://hubs.ly/Q01-675L0 #Healthcare #HealthPlans #PayerProviderCollaboration #RecessionProof

Dive into Volume 12, Issue 1 (February 2024) 📚💊 📅 Released: February 2024 Ready to elevate your understanding of pharmacy? Click below to explore the future of healthcare! 👉 https://lnkd.in/ddkp6zQ7 #Pharmacy #Research #Innovation #Healthcare #NewRelease

New name, same great content! Biosimilars are transforming the healthcare landscape, but how are managed care organizations evaluating these new options? Check out my most recent interview with the very knowledgeable Dr. Nisha Bhide, PharmD, as we discuss the key factors managed care considers when navigating the biosimilar space. We delve into topics like cost-effectiveness, clinical data, and provider adoption. Get ready for insider perspectives to help you understand biosimilars through the lens of managed care. Thank you so much for joining me Dr. Bhide! #managedcare #biosimilars #valueexchange #PTCE #PTCEManagedCare #pharmacy